ValuentumAd

Official PayPal Seal

Novartis Closes Out Busy Year; Proposes Dividend Hike

publication date: Jan 30, 2019
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.


Image Source: Novartis fourth quarter presentation. 

European pharmaceutical giant Novartis had a busy year in 2018 on its quest to renew its focus on medicines, and management is excited about its future growth trajectory. We continue to like its free cash flow generation and dividend growth potential.



Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.